FDA Tobacco Regulatory Science Fellowship
- Fellowship Program
- Health Policy Educational Programs and Fellowships
The Call for Applications for the 2012-2013 fellowship is now closed. The Call for Applications for the 2013-2014 fellowship will become available in January 2013.
The Food and Drug Administration Center for Tobacco Products (CTP), in collaboration with the Institute of Medicine (IOM), is launching a new regulatory science fellowship program designed for mid-career professionals to gain experience and expertise to further define and develop the field of regulatory science as it relates to the regulation of tobacco products and FDA’s new authorities under the Family Smoking Prevention and Tobacco Control Act. This is an excellent opportunity for exceptional, highly competitive professionals to actively participate in the development of science-based public health strategies, serve as the lead for defined projects, meet with policy leaders, and develop new competencies, including new knowledge, skills, and experiences related to tobacco products and their use, which is the leading cause of preventable death in the United States.
The fellowship is a 12-month, multidisciplinary residential program in Rockville, MD, starting September 2012. Fellows will be placed in one of three offices within the CTP: the Office of Health Communication and Education, the Office of Policy, and the Office of Science.
Fellows are expected to complete the full 12-month residential fellowship in Rockville, MD. Each fellow will be awarded up to $95,000. In addition, each fellow will receive a relocation fund (not to exceed $10,000).
Exceptional, highly competitive professionals with a minimum of five to seven years of experience are encouraged to apply. All applicants must be U.S. citizens or U.S. nationals with advanced degrees in the fields listed below.
- Behavioral Science
- Biomedical Science
- Biomedical Engineering
- Consumer Education
- Economics, Political Science, and other Social Sciences such as Sociology, Anthropology, and Psychology
- Public Health, including Public Health Ethics
- Public Policy/Public Administration
- Social and Behavioral Health
Selection Criteria Fellows will be selected through a national competition on basis of:
- Professional Achievements
- Quality of Essays
- Expertise in an Area of Relevance to the CTP
- Quality of Letters of Recommendation
The online application will become available on June 4, 2012. All application materials must be submitted via the electronic application system. The complete application package includes:
- Curriculum Vitae (C.V.)
- A One-Page Biography
- Three (3) Letters of Recommendation
- Two (2) Short Essays
The deadline to submit all application materials is June 18, 2012.
|June 4-18||Online Applications Accepted|
|June 25 or 26||Selection of Finalists for In-Person Interviews|
|June 26||Notification of Finalists|
|July 18 or 19||In-Person Interviews in Washington, DC|
|July 19||Notification of Awardees|
|September 10||Start of Fellowship|
The FDA Tobacco Regulatory Science Fellowship is administered by the IOM and sponsored by the FDA/CTP. All inquiries should be directed to:
FDA Tobacco Regulatory Science Fellowship
500 Fifth Street, NW
Keck WS 702
Washington, DC 20001
The Food and Drug Administration is the regulatory, scientific, public health and consumer protection agency responsible for ensuring that all human and animal drugs, and medical devices are safe and effective, that cosmetics, foods, food additives, drugs and medicated feeds for food producing animals, and radiation emitting devices are safe, and for regulating tobacco products to protect the public health.
Center for Tobacco Products (CTP)
The CTP was established by the Tobacco Control Act, which was signed into law by President Barack Obama on June 22, 2009. Its mission is to protect Americans from tobacco-related death and disease by regulating the manufacture, marketing, and distribution of tobacco products, and by educating the public, especially young people, about tobacco products and the dangers their use poses to themselves and others.
Office of Health Communication and Education
The CTP Office of Health Communication and Education is responsible for educating the public about the Tobacco Control Act, FDA’s regulatory authorities, and about the tobacco products FDA regulates. Based on specific statutory authorities, this Office develops and implements compelling, relevant and effective public education strategies and campaigns related to FDA tobacco product regulation, which are designed to keep young people from starting to use tobacco products and encouraging tobacco users to quit. This Office also creates public education strategies to provide accurate information to all Americans about the contents of tobacco products and the consequences of tobacco use. The Office of Health Communication and Education relies heavily on the expertise of behavioral scientists, tobacco and public health experts in risk communications, and other professionals with experience in public education, marketing, and advertising.
Office of Policy
The CTP Office of Policy works closely with the CTP Director and all CTP Offices to provide policy, legal1 and economic analysis on a wide range of CTP priorities and issues. The Office assures that CTP’s statutory public health goals and policy needs are integrated across all CTP science, regulation, compliance, public education, and management programs. The Office provides economic analysis and modeling of CTP policy options, and works closely with all CTP Offices on evolving issues in tobacco product regulation and control, such as impact on population health, development of tobacco product standards, modified risk products, and the regulation of tobacco product marketing. The Office engages with external stakeholders to inform and educate them about the policy implications of the Tobacco Control Act and FDA regulations and to gather useful facts and insights. The Office relies on individuals with expertise and backgrounds in the law, economics, public policy, and public health.
Office of Science
The CTP Office of Science is responsible for identifying, developing, and enhancing the science related to tobacco products, their use, and the resulting morbidity and mortality so that regulatory decisions will have the greatest impact on improving public health. To accomplish this goal, the Office of Science provides the scientific expertise needed to support regulatory decisions , reviews tobacco product applications, evaluates the knowledge base for regulatory decisions, and carries out research to fill the gaps in scientific knowledge related to tobacco product regulation. The Office is responsible for building on and maintaining a scientific base for establishing tobacco policies, product standards, and test methods appropriate for the protection of public health. The Office conducts product-related, toxicological, clinical, consumer behavior, epidemiological, and consumer perception research regarding the initiation, use, cessation, and adverse health impact of tobacco products. The Office of Science has a particular interest in: methods of reporting and analyzing constituent concentrations in tobacco products; analysis of exposure parameters in diverse tobacco-using populations; the toxicological basis of dose-response relationships between constituents and tobacco-related disease; and assessing the risks of tobacco products to users and non-users. The Office relies on the expertise of both biomedical and social scientists and is especially interested in fellowship candidates with backgrounds in pharmacology/toxicology and human health risk assessment modeling, qualitative, and quantitative research on the impacts of product labeling, advertising, and/or marketing on consumer perceptions and behaviors. The Office also is especially interested in epidemiologists with backgrounds in both clinical studies and large surveys evaluating the impact of tobacco product use on biomarkers of exposure and disease.
1Legal analysis required for official FDA/HHS decision-making and regulation is provided by the Food and Drug Law Division of the HHS Office of General Counsel.